PMC:7279430 / 24303-25114
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T63 | 256-259 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T64 | 270-273 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T65 | 347-354 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T66 | 470-478 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
953 | 126-130 | Gene | denotes | Mpro | Gene:8673700 |
954 | 297-301 | Gene | denotes | RdRp | Gene:43740578 |
955 | 341-346 | Gene | denotes | spike | Gene:43740568 |
956 | 382-411 | Gene | denotes | angiotensin-converting enzyme | Gene:1636 |
957 | 413-418 | Gene | denotes | hACE2 | Gene:59272 |
958 | 89-99 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
959 | 115-125 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
960 | 133-143 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
961 | 163-173 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
962 | 189-199 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
963 | 227-237 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
964 | 245-255 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
965 | 286-296 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
966 | 330-340 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
967 | 356-366 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
968 | 376-381 | Species | denotes | human | Tax:9606 |
969 | 454-462 | Species | denotes | SARS-CoV | Tax:694009 |
970 | 487-491 | Species | denotes | E)-α | Tax:114629 |
971 | 503-518 | Chemical | denotes | (E)-β-farnesene | |
972 | 524-538 | Chemical | denotes | (E,E)-farnesol | |
973 | 654-667 | Chemical | denotes | essential oil | MESH:D009822 |
974 | 704-718 | Chemical | denotes | essential oils | MESH:D009822 |
975 | 793-801 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T128 | 89-97 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T129 | 115-123 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T130 | 133-141 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T131 | 163-171 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T132 | 189-197 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T133 | 227-235 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T134 | 245-253 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T135 | 286-294 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T136 | 330-338 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T137 | 356-364 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T138 | 454-462 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T139 | 793-801 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T166 | 0-1 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T167 | 367-369 | http://purl.obolibrary.org/obo/CLO_0008882 | denotes | rS |
T168 | 376-381 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T169 | 630-635 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T381 | 55-79 | Chemical | denotes | essential oil components | http://purl.obolibrary.org/obo/CHEBI_27311 |
T382 | 55-68 | Chemical | denotes | essential oil | http://purl.obolibrary.org/obo/CHEBI_83630 |
T383 | 200-203 | Chemical | denotes | ADP | http://purl.obolibrary.org/obo/CHEBI_16761|http://purl.obolibrary.org/obo/CHEBI_456216|http://purl.obolibrary.org/obo/CHEBI_73342 |
T386 | 204-210 | Chemical | denotes | ribose | http://purl.obolibrary.org/obo/CHEBI_33942|http://purl.obolibrary.org/obo/CHEBI_47013 |
T388 | 347-354 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T389 | 382-393 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
T390 | 438-445 | Chemical | denotes | ligands | http://purl.obolibrary.org/obo/CHEBI_52214 |
T391 | 470-478 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T392 | 492-501 | Chemical | denotes | farnesene | http://purl.obolibrary.org/obo/CHEBI_39237 |
T393 | 509-518 | Chemical | denotes | farnesene | http://purl.obolibrary.org/obo/CHEBI_39237 |
T394 | 524-538 | Chemical | denotes | (E,E)-farnesol | http://purl.obolibrary.org/obo/CHEBI_16619 |
T395 | 530-538 | Chemical | denotes | farnesol | http://purl.obolibrary.org/obo/CHEBI_28600 |
T396 | 654-678 | Chemical | denotes | essential oil components | http://purl.obolibrary.org/obo/CHEBI_27311 |
T397 | 654-667 | Chemical | denotes | essential oil | http://purl.obolibrary.org/obo/CHEBI_83630 |
T398 | 704-718 | Chemical | denotes | essential oils | http://purl.obolibrary.org/obo/CHEBI_83630 |
T399 | 740-756 | Chemical | denotes | antiviral agents | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T17 | 214-225 | http://purl.obolibrary.org/obo/GO_0016791 | denotes | phosphatase |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T177 | 0-420 | Sentence | denotes | A molecular docking analysis was carried out using 171 essential oil components with the SARS-CoV-2 main protease (SARS-CoV-2 Mpro), SARS-CoV-2 endoribonucleoase (SARS-CoV-2 Nsp15/NendoU), SARS-CoV-2 ADP-ribose-1″-phosphatase (SARS-CoV-2 ADRP), SARS-CoV-2 RNA-dependent RNA polymerase (SARS-CoV-2 RdRp), the binding domain of the SARS-CoV-2 spike protein (SARS-CoV-2 rS), and human angiotensin-converting enzyme (hACE2). |
T178 | 421-539 | Sentence | denotes | The best docking ligands for the SARS-CoV target proteins were (E,E)-α-farnesene, (E)-β-farnesene, and (E,E)-farnesol. |
T179 | 540-644 | Sentence | denotes | The docking energies were relatively weak, however, and are unlikely to interact with the virus targets. |
T180 | 645-811 | Sentence | denotes | However, essential oil components may act synergistically, essential oils may potentiate other antiviral agents, or they may provide some relief of COVID-19 symptoms. |